cell line
development
with leap-in transposase®
ATUM's Leap-In transposases and synthetic transposons enable a cost-effective, easily implemented cell line development workflow encompassing cell line generation and cell line engineering. ATUM's Leap-In technology delivers high productivity pools and cell lines, resulting in consistent product quality. With Leap-In technology, also licensable for your in-house use, discover how ATUM’s cell line development technology can support your projects and speed it up to IND.
Yield
Maximize your yield with ATUM's Leap-In technology! Our proprietary platform generates highly productive stable pools, with pool titers very predictive of final clonal line titers.
Stability
Exceptional genetic stability leads to stable productivity of Leap-in-generated clonal cell lines. Derisk your workflow, from downstream process development to scale-up and manufacturing, with ATUM's stable cell lines platform.
Speed
Shave months off your CMC timeline with ATUM. With highly comparable quality and productivity between stable pools and derivative clones, get a head start on your analytical development, process development, and GLP toxicology studies.
Efficiency
With ATUM's Leap-In technology, cell line development is less labor intensive and does not require automation. No matter how small your team, many projects can be conducted simultaneously, from cell line development to cell line generation and cell line engineering.
Leap-In Transposases Integrate Intact DNA Constructs into Active Chromatin
LEAP-IN TRANSPOSASE®
Leap-In Transposases Integrate Intact DNA Constructs into Active Chromatin
By integrating single copies of the entire synthetic transposon into multiple transcriptionally active genomic loci, ATUM’s Leap-In transposases will advance your cell line development workflow by:
- De-risking your workflow – By integrating the entire transposon, ATUM’s Leap-In transposases removes the risk of expression construct rearrangement or concatemerization, both common and problematic hallmarks of integration driven by random non-homologous recombination.
- Increasing Open Reading Frame stability - By maintaining structural integrity of the integrated sequence, ATUM's Leap-In Transposase ensures that regulatory elements remain associated with the appropriate open reading frames, and that multiple open reading frames are in the desired balance.
- Facilitating gene co-expression - Leap-In Transposase provides a very effective way to integrate genes that need to be expressed together as well as balancing respective gene expression in a controlled and optimal way, for example the heavy and light chains from monoclonal antibodies, or the three to four chains of bispecific antibodies.
How Leap-In Transposase Works
01
A synthetic transposon, comprising the expression construct and selection marker, flanked by inverted terminal repeats (ITRs).
02
Leap-In transposase recognizes its specific ITRs, binds and excises the transposon.
03
Leap-In transposase recognizes 4-base insertion sites across the host cell genome.
04
The intact transposon is inserted at up to 60 or more loci across the genome.
Expression Balancing and Optimization with VectorGPS®
Expression Balancing and Optimization with VectorGPS®
Using our VectorGPS® design platform, we can design, synthesize and transfect multiple synthetic transposons in parallel, each harboring up to 4 independently-controlled, codon-optimized ORFs with altered expression ratios. Furthermore, we can identify the optimal construct with our stable pool productivity and product quality. This means the balance of expression for each subunit in a multi-subunit protein can be optimized for increased productivity and product quality. Using ATUM's VectorGPS®, you can decrease the risk of incomplete correlation between the best ratios of transiently transfected genes, and the optimal stable expression of each subunit.
Leap-In Transposon
2 ORFs
Leap-In Transposon
3 ORFs
Leap-In Transposon
4 ORFs
Control of protein subunit expression ratios in 2-, 3- and 4-ORF Leap-In transposons.
Our Mammalian Hosts
CELL LINE DEVELOPMENT WORKFLOW
Our Mammalian Hosts
ATUM currently uses three mammalian host cell lines with lineage traceability and documented provenance. All CHO cell lines are adapted to commercially-available chemically-defined serum-free formulations. No raw materials of animal origin are used during CHO cell line generation or our cell line development process.
Stable Pool Selection
ATUM's Leap-In transposase can increase the efficiency of your stable expression cell line construction. With most Leap-In transfected cells integrating multiple copies of the transposon into their genomes, ATUM's technology ensures:
- Rapid recovery of stable pools consisting of many very similar cells.
- Highly comparable productivity and product quality of clones derived from these pools and the pools themselves.
- Early initiation of process and analytical development at just a few weeks post-transfection.
- Shorter overall CMC timelines due to the ability to prepare material for toxicology studies from stable pools.
Productivity
Product Quality
Product quality (glycan relative abundance %, charge %) and productivity is comparable between stable pool and derivative clones.
Clone Isolation
Clone Isolation
The clonal distribution within the stable pools generated by ATUM's Leap-In technology, are strongly biased towards high productivity. This reduces the number of clones that need to be tested to no more than a few hundred. Using Solentim VIPS™ seeding and clonal identification instruments, ATUM efficiently isolates high producing clones.
166 clones
Static 96 well plate
22 clones
24 deep-well scale, 7 day fed batch clone ranking
8 clones
Highest ranked clones, 125 ml shake, 14 day fed batch
Screening, characterizing and ranking fewer clones eliminates the need to invest in expensive, high-throughput instrumentation for cell line engineering and allows more cell line development projects to be managed simultaneously.
Stability Testing - Stable Expression Cell Lines
Stability Testing - Stable Expression Cell Lines
ATUM's Leap-In transposases ensure your integration structures are stably maintained through an effective process:
- Leap-In Transposase mRNA is co-transfected with the synthetic transposon into the cell.
- The mRNA is translated and the Leap-In transposase protein transiently acts to integrate the transposon into the host genome.
- The transposase mRNA is degraded through the normal cellular RNA turnover pathways.
This means there is no way for the cell to generate transposase to mobilize the transposon, which contains your genes and constructs, and disrupt their stability. Because each integration contains a single copy of the transposon, there is no instability resulting from concatemer recombination or repeat-induced silencing. The number of integration could be as high as 60 which is a guarantee of high titers as the integration number of transposons correlated with the protein yield.
Cell line construction Clonal cell lines are grown for 60 populations doublings then assayed for genetic stability by ddPCR, and productivity stability. The majority of clones created using Leap-In technologies exhibit no significant decreases in their volumetric productivity and integrated transposon copy number. Research cell banks (RCB) are established from the top performing clones. Cell banks are released after testing for sterility, mycoplasma, and transgene integrity by Southern blot and cDNA sequence analysis.
Productivity maintained
Copy number maintained
Pie charts show the maintenance of productivity and transposon copy number in clonal cell lines after 60 population doublings. Data is taken from 47 clones created using Leap-In technologies. All clones retained at least 70% of their initial productivity and transposon copy number.
CELL LINE DEVELOPMENT
TIMELINE
Licensing leap-in
transposase®
Bring the advantages of ATUM's Leap-In technology to your in-house cell line development. The unique Leap-In transposase technology is covered by many issued and pending US patents, ensuring a broad integrated portfolio of related tools to maximize your success in cell line development and cell line engineering. The portfolio includes not only the Leap-In transposon/transposase itself but also complementing tools such as vector optimization, unique vector elements, codon optimization and more to provide you with our state-of-the-art bioengineering expertise. For the currently issued patents and related claims, please see our patents list.
We offer three convenient tiers of licensing to meet your research and commercialization needs. Under all licenses, Leap-In transposase mRNA and synthetic transposon DNA are purchased from ATUM. Your gene and vector designs are supported by our experienced Leap-In team and synthesized by ATUM to maximize your chance for success.
Evaluation
Test and optimize the Leap-In technology in your labs. Convert to a full research license after 6 months or terminate if the Leap-In technology is not for you. Benefit from a quick low-cost opportunity to take the Leap-In system out for a spin.
Research
With a simple annual license fee, get access to existing and new transposon and transposase technology as it is continuously developed at ATUM. This licensing tier is great for all your research use only (RUO) applications.
Commercialization
ATUM offers a licensing tier for commercial production of your protein pharmaceutical or similar. Payment is simple - payable on cell lines that enable commercialization of your therapeutic, diagnostic or product - pay annually, as a single lump sum, or attached to clinical milestones.
Contact our cell line development scientists for quotes or to answer any questions you may have about our cell line development services.
CASE STUDIES
Have a question?
Let's talk.
ATUM customer support scientists are available to discuss cloning strategies, gene design constraints, bioinformatics analyses, and other molecular biology/biotechnology concerns.
Call
Corporate Headquarters
(Newark, California)
+1 650 853 8347
